[go: up one dir, main page]

CN111803529A - A compound microecological preparation for preventing calf diarrhea - Google Patents

A compound microecological preparation for preventing calf diarrhea Download PDF

Info

Publication number
CN111803529A
CN111803529A CN202010702682.6A CN202010702682A CN111803529A CN 111803529 A CN111803529 A CN 111803529A CN 202010702682 A CN202010702682 A CN 202010702682A CN 111803529 A CN111803529 A CN 111803529A
Authority
CN
China
Prior art keywords
calves
diarrhea
lactobacillus acidophilus
saccharomyces
probiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010702682.6A
Other languages
Chinese (zh)
Inventor
张文举
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shihezi University
Original Assignee
Shihezi University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shihezi University filed Critical Shihezi University
Priority to CN202010702682.6A priority Critical patent/CN111803529A/en
Publication of CN111803529A publication Critical patent/CN111803529A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/064Saccharomycetales, e.g. baker's yeast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/742Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

本发明为一种预防犊牛腹泻的复合微生态制剂。一种预防犊牛腹泻的复合微生态制剂,含有嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌。本发明通过对分离鉴定腹泻犊牛粪便中致病性大肠杆菌,对嗜酸乳杆菌、布拉迪酵母菌、枯草芽孢杆菌3株益生菌在耐酸性、耐胆盐及抑菌性生物学特性比较分析发现,三株益生菌均具有较好的耐受性,并通过对三株益生菌的混配对抑制大肠杆菌k99具有较好的抑菌效果;在哺乳期犊牛上进行了应用,它还具有提高犊牛日增重,增加犊牛采食量,降低腹泻率、提高犊牛免疫性能和抗氧化性能的作用,可以调节动物肠道菌群。

Figure 202010702682

The invention is a composite microecological preparation for preventing calf diarrhea. A compound probiotic for preventing diarrhea in calves, containing Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis. The present invention separates and identifies pathogenic Escherichia coli in the feces of calves with diarrhea, and has the biological characteristics of acid resistance, bile salt resistance and bacteriostasis to three probiotic bacteria of Lactobacillus acidophilus, Saccharomyces bodrum and Bacillus subtilis. The comparative analysis found that the three probiotics had good tolerance, and the mixture of the three probiotics had a good bacteriostatic effect on Escherichia coli k99; It can also increase the daily weight gain of calves, increase the feed intake of calves, reduce the rate of diarrhea, improve the immune performance and antioxidant performance of calves, and can regulate the intestinal flora of animals.

Figure 202010702682

Description

一种预防犊牛腹泻的复合微生态制剂A compound microecological preparation for preventing calf diarrhea

技术领域technical field

本发明属于牲畜领域,具体涉及一种预防犊牛腹泻的复合微生态制剂。The invention belongs to the field of livestock, and in particular relates to a composite microecological preparation for preventing calf diarrhea.

背景技术Background technique

在过去的几十年里,抗生素在防治畜禽感染、抵抗疾病方面使用量逐年增加,据报道中国是世界上抗生素生产和消费最多的国家,给畜牧业发展带来生产效益的同时,人类和畜禽所处的生态环境及健康状况也面临的巨大风险,这也导致了人类的生活环境、畜禽养殖环境、畜禽机体等中的病原体和常见细菌耐药性的上升。因此在2003年,全球逐步禁止使用抗生素瑞典与1986年禁止使用抗生素,欧盟也于2006年禁止使用抗生素。随着全球范围内禁止使用抗生素生长促进剂(AGPS)的趋势日益严峻,导致对AGPS替代品的需求日益迫切。In the past few decades, the use of antibiotics in the prevention and control of livestock and poultry infections and disease resistance has increased year by year. It is reported that China is the country with the largest production and consumption of antibiotics in the world. While bringing production benefits to the development of animal husbandry, human and The ecological environment and health status of livestock and poultry also face huge risks, which has also led to the rise of drug resistance of pathogens and common bacteria in human living environment, livestock and poultry breeding environment, and livestock and poultry bodies. Therefore, in 2003, the world gradually banned the use of antibiotics in Sweden and 1986, and the European Union also banned the use of antibiotics in 2006. The growing global trend towards banning the use of antibiotic growth promoters (AGPS) has led to an increasingly urgent need for alternatives to AGPS.

犊牛作为奶牛养殖业的后备力量,对于奶牛生产潜力的发挥具有至关重要的作用,而犊牛腹泻(Calf diarrhea)是导致犊牛死亡的主要原因。犊牛腹泻是一种常见疾病,对犊牛生长发育危害巨大,其病因复杂,是当前犊牛多发病之一,给养牛业带来较大经济损失。据统计新疆北疆垦区规模化发病率占40-60%不等,死亡率50-70%,导致犊牛腹泻的微生物因素主要有细菌性(平均发病率36.7%)和病毒性(平均发病率7.5%)因素。As the backup force of dairy farming, calves play a vital role in the production potential of dairy cattle, and calf diarrhea is the main cause of calf death. Calf diarrhea is a common disease, which is harmful to the growth and development of calves, and its etiology is complex. According to statistics, the large-scale morbidity in the northern Xinjiang reclamation area accounts for 40-60%, and the mortality rate is 50-70%. The microbial factors leading to calf diarrhea are mainly bacterial (average morbidity rate 36.7%) and viral (average morbidity rate). 7.5%) factor.

研究发现引起新疆地区近两年来犊牛腹泻的致病性大肠杆菌对氨苄西林、庆大霉素、氯霉素和环丙沙星等抗生素均产生不同程度的耐药性。因此,目前迫切需要寻找替代抗生素作为预防性抗菌药物的替代方案。为了提高动物福利和保护环境,饲用微生物因其具有无污染、无残留、绿色的特点且具有提高畜禽生长性能、优化肠道菌群、提高动物机体免疫力等生物学功能而备受关注,许多研究也正是饲用微生态制剂已被认为是潜在的替代品。The study found that the pathogenic Escherichia coli that caused diarrhea in calves in Xinjiang in the past two years had different degrees of resistance to antibiotics such as ampicillin, gentamicin, chloramphenicol and ciprofloxacin. Therefore, there is an urgent need to find alternatives to antibiotics as prophylactic antimicrobials. In order to improve animal welfare and protect the environment, feed microorganisms have attracted much attention because of their non-polluting, non-residue, green characteristics, and their biological functions such as improving the growth performance of livestock and poultry, optimizing intestinal flora, and improving animal immunity. , many studies are also that forage probiotics have been considered as potential substitutes.

有鉴于此,本发明提出一种新的预防犊牛腹泻的复合微生态制剂,可以替代抗生素、预防幼龄犊牛消化道疾病。In view of this, the present invention proposes a new compound microecological preparation for preventing calf diarrhea, which can replace antibiotics and prevent digestive tract diseases of young calves.

发明内容SUMMARY OF THE INVENTION

本发明的目的在于提供一种预防犊牛腹泻的复合微生态制剂,可以替代抗生素、预防幼龄犊牛消化道疾病。The purpose of the present invention is to provide a composite microecological preparation for preventing calf diarrhea, which can replace antibiotics and prevent digestive tract diseases of young calves.

为了实现上述目的,所采用的技术方案为:In order to achieve the above purpose, the adopted technical scheme is:

一种预防犊牛腹泻的复合微生态制剂,所述的复合微生态制剂含有嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌。A composite microbial preparation for preventing diarrhea in calves, the composite microbial preparation contains Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis.

进一步地,所述的嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌的活菌数之比为1-3:1-3:1-3。Further, the ratio of the viable counts of Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis is 1-3:1-3:1-3.

再进一步地,所述的嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌的活菌数之比为1:2:1或3:3:1。Still further, the ratio of the viable counts of Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis is 1:2:1 or 3:3:1.

再进一步地,所述的嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌的活菌数之比为3:3:1。Still further, the ratio of the number of viable cells of the Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis is 3:3:1.

进一步地,所述的复合微生态制剂为液态制剂。Further, the composite microbial preparation is a liquid preparation.

再进一步地,所述的复合微生态制剂由活菌数浓度均为1×109cfu/mL嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌配比而成。Still further, the composite microecological preparation is formed by the proportion of Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis, all of which have a viable bacterial count concentration of 1×10 9 cfu/mL.

进一步地,所述的复合微生态制剂用于预防犊牛大肠杆菌K99导致的腹泻。Further, the compound probiotic preparation is used to prevent diarrhea caused by Escherichia coli K99 in calves.

与现有技术相比,本发明的有益效果在于:Compared with the prior art, the beneficial effects of the present invention are:

本发明以分离致病性大肠杆菌k99和实验室保藏的益生菌为研究对象,比较分析各益生菌株间的生物学特性,筛选出最佳抑制预防犊牛腹泻复合微生态制剂3株菌种的配比优化组合。为开发防治犊牛腹泻的微生态制剂提供理论基础。The invention takes the isolation of pathogenic Escherichia coli k99 and the probiotics preserved in the laboratory as the research objects, compares and analyzes the biological characteristics of the probiotic strains, and selects 3 strains of the compound microecological preparation that best inhibits and prevents calf diarrhea. Proportion optimization combination. It provides a theoretical basis for the development of microecological preparations for the prevention and treatment of calf diarrhea.

同时,本发明的技术方案具有提高犊牛日增重,增加犊牛采食量,降低腹泻率、提高犊牛免疫性能和抗氧化性能的作用,可以调节动物肠道菌群。At the same time, the technical solution of the present invention has the functions of increasing the daily weight gain of the calf, increasing the feed intake of the calf, reducing the diarrhea rate, improving the immune performance and the antioxidant performance of the calf, and can regulate the intestinal flora of animals.

附图说明Description of drawings

图1为大肠杆菌的镜检图;Fig. 1 is the microscope picture of Escherichia coli;

图2为大肠杆菌k99扩增图;Fig. 2 is the amplification diagram of Escherichia coli k99;

图3为NCBI Genbank进行BLAST结果图;Figure 3 is a graph of the results of BLAST performed by NCBI Genbank;

图4为嗜酸乳杆菌人工胃液不同PH值的耐受性;Fig. 4 is the tolerance of different pH values of Lactobacillus acidophilus artificial gastric juice;

图5为芽孢杆菌人工胃液不同PH值的耐受性;Fig. 5 is the tolerance of different pH values of Bacillus artificial gastric juice;

图6为布拉迪酵母菌人工胃液不同PH值的耐受性;Fig. 6 is the tolerance of different pH values of Saccharomyces boulardii artificial gastric juice;

图7为3种益生菌人工肠液不同时间的耐受性;Figure 7 shows the tolerance of three probiotic artificial intestinal fluids at different times;

图8为3种益生菌牛胆盐的耐受性图。Figure 8 is a graph showing the tolerance of 3 kinds of probiotic bovine bile salts.

具体实施方式Detailed ways

为了进一步阐述本发明一种预防犊牛腹泻的复合微生态制剂,达到预期发明目的,以下结合较佳实施例,对依据本发明提出的一种预防犊牛腹泻的复合微生态制剂,其具体实施方式、结构、特征及其功效,详细说明如后。在下述说明中,不同的“一实施例”或“实施例”指的不一定是同一实施例。此外,一或多个实施例中的特定特征、结构或特点可由任何合适形式组合。In order to further describe the composite microbial preparation for preventing calf diarrhea according to the present invention and achieve the intended purpose of the invention, the following specific implementation of the composite microbial preparation for preventing calf diarrhea proposed according to the present invention in conjunction with the preferred embodiments The method, structure, characteristics and efficacy thereof are described in detail as follows. In the following description, different "an embodiment" or "embodiments" do not necessarily refer to the same embodiment. Furthermore, the particular features, structures or characteristics in one or more embodiments may be combined in any suitable form.

下面将结合具体的实施例,对本发明一种预防犊牛腹泻的复合微生态制剂做进一步的详细介绍:Below in conjunction with specific embodiment, a kind of composite microecological preparation for preventing calf diarrhea of the present invention will be further introduced in detail:

本方面通过采用分子生物学方法分离鉴定腹泻犊牛粪便中致病性大肠杆菌k99。同时对嗜酸乳杆菌、布拉迪酵母菌、枯草芽孢杆菌3株益生菌在耐酸性、耐胆盐及抑菌性生物学特性比较分析发现,在pH为3时,存活率为84.34%。芽孢杆菌在pH为5时,存活率为142.24%;在人工胃液中9小时存活率都很高,与0小时的OD600相比,布拉迪酵母菌和嗜酸乳杆存活率分别为108.7%、129.73%,嗜酸乳杆菌达到了96.37%。在含有不同浓度的牛胆盐培养基中,布拉迪酵母菌存活率较对照组的存活率最高为60.49%,嗜酸乳杆菌存活率较对照组最高为85.1%,芽孢杆菌存活率较对照组的存活率最高为47.42%。三株益生菌对大肠杆菌、沙门氏菌均有一定的抑菌特性。说明布三株益生菌对人工胃液、人工肠液、牛胆盐具有较好的耐受性,并具有一定的抑菌性。In this aspect, pathogenic Escherichia coli k99 is isolated and identified in the feces of calves with diarrhea by using molecular biology methods. At the same time, the comparative analysis of the biological characteristics of acid resistance, bile salt resistance and bacteriostasis of Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis showed that at pH 3, the survival rate was 84.34%. Bacillus at pH 5, the survival rate was 142.24%; in artificial gastric juice, the survival rate was high at 9 hours, compared with OD 600 at 0 hours, the survival rate of Saccharomyces boulardii and Lactobacillus acidophilus were 108.7 %, 129.73%, Lactobacillus acidophilus reached 96.37%. In the medium containing bovine bile salts with different concentrations, the survival rate of Saccharomyces boulardii was the highest compared with the control group, which was 60.49%, the survival rate of Lactobacillus acidophilus was the highest compared with the control group, 85.1%, and the survival rate of Bacillus was higher than that of the control group. The highest survival rate of the group was 47.42%. The three strains of probiotics have certain antibacterial properties against Escherichia coli and Salmonella. The results indicated that the three probiotics had good tolerance to artificial gastric juice, artificial intestinal juice and bovine bile salts, and had certain bacteriostatic properties.

通过对三株益生菌的不同配比抑制大肠杆菌k99发现,三种益生菌按照不同配比在培养12h后,试验组第1、2、3、4、5、6、7、8、9组较对照组相比差异显著(P<0.05),与第2、4、8组之间差异显著(P<0.05);在培养24h后,试验组第2、3、4、5、6、8较对照组相比差异显著(P<0.05),但第2、3、4、5、6、8之间差异不显著(P>0.05)。第8个处理组在培养12h后对大肠杆菌K99的抑菌效果较好,从而可以确定嗜酸乳杆菌、枯草芽孢杆菌、布拉迪酵母菌最佳的复配比例为3:3:1。为开发替代抗生素、预防幼龄犊牛消化道疾病微生态制剂提供理论基础。By inhibiting Escherichia coli k99 with different ratios of the three probiotics, it was found that the three probiotics were cultured for 12 hours according to different ratios, and the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, and 9th groups of the experimental group Compared with the control group, the difference was significant (P<0.05), and the difference was significant (P<0.05) between groups 2, 4, and 8; Compared with the control group, the difference was significant (P<0.05), but the difference between the 2nd, 3rd, 4th, 5th, 6th, and 8th was not significant (P>0.05). The eighth treatment group had better bacteriostatic effect on Escherichia coli K99 after culturing for 12 hours, so it could be determined that the optimal compounding ratio of Lactobacillus acidophilus, Bacillus subtilis, and Saccharomyces boulardii was 3:3:1. It provides a theoretical basis for the development of microecological preparations to replace antibiotics and prevent digestive tract diseases in young calves.

具体操作步骤如下:The specific operation steps are as follows:

一微生物制剂对幼龄犊牛消化道疾病的影响The effect of microbiological preparations on digestive tract diseases of young calves

1材料与方法1 Materials and methods

1.1试验材料1.1 Test material

(1)试验菌株(1) Test strains

益生菌菌株:嗜酸乳杆菌(Lactobacillus acidophilus)、布拉迪酵母菌(Saccharomyces boulardii)、枯草芽孢杆菌(Bacillus subtilis),由石河子大学动物科技学院生物饲料实验室提供。Probiotic strains: Lactobacillus acidophilus, Saccharomyces boulardii, Bacillus subtilis, provided by Biofeed Laboratory, School of Animal Science and Technology, Shihezi University.

试验病菌:大肠杆菌(K99)自主分离;沙门氏菌、金黄色葡萄球菌购买于上海鲁微科技有限公司。Test bacteria: Escherichia coli (K99) was independently isolated; Salmonella and Staphylococcus aureus were purchased from Shanghai Luwei Technology Co., Ltd.

(2)培养基:(2) Culture medium:

LB营养琼脂培养基、LB肉汤、麦康凯琼脂培养基、MRS液体培养基、MRS固体培养基、YPD液体培养基、YPD固体培养基、芽孢杆菌培养基均购买于青岛高科园海博生物技术有限公司。LB nutrient agar medium, LB broth, MacConkey agar medium, MRS liquid medium, MRS solid medium, YPD liquid medium, YPD solid medium and Bacillus medium were purchased from Qingdao Hi-Tech Park Haibo Biotechnology Ltd.

(3)主要试剂(3) Main reagents

PBS缓冲液,用于菌液的稀释。细菌DNA提取试剂盒购于天根生化科技有限公司;胃蛋白酶、胰蛋白酶、牛胆盐购买于Beijing Biotopped Science&Technology Co.,Ltd。生理生化鉴定管购于杭州滨河微生物试剂有限公司。K99引物由上海捷瑞生物技术有限公司合成,测序由华大基因有限公司完成。PBS buffer for bacterial dilution. Bacterial DNA extraction kits were purchased from Tiangen Biochemical Technology Co., Ltd.; pepsin, trypsin, and ox bile salts were purchased from Beijing Biotopped Science&Technology Co., Ltd. Physiological and biochemical identification tubes were purchased from Hangzhou Binhe Microbial Reagent Co., Ltd. The K99 primer was synthesized by Shanghai Jierui Biotechnology Co., Ltd., and the sequencing was completed by Huada Gene Co., Ltd.

(4)主要器材(4) Main equipment

移液枪;电子天平JM-500,昆山金珂华电子有限公司,电子天平BS224S,北京赛多利斯仪器有限公司;酸度计WTW PH3110,凯铭态仪器;立式超低温保温箱GSP-9160MBE、恒温培养箱HPX-9162MBE、超净工作台SW-CJ-2F,上海博讯实业有限公司医疗设备厂;酶标仪WD-2102B,BEIJING北京六一生物科技有限公司;PCR仪,上海纳兹仪器有限公司。离心机TG16-W,湘南湘仪实验室仪器开发有限公司Pipette gun; electronic balance JM-500, Kunshan Jinkehua Electronics Co., Ltd., electronic balance BS224S, Beijing Sartorius Instrument Co., Ltd.; acidity meter WTW PH3110, Kaiming state instrument; vertical ultra-low temperature incubator GSP-9160MBE, constant temperature incubator HPX-9162MBE, ultra-clean workbench SW-CJ-2F, Shanghai Boxun Industrial Co., Ltd. Medical Equipment Factory; microplate reader WD-2102B, BEIJING Beijing Liuyi Biotechnology Co., Ltd.; PCR instrument, Shanghai Naz Instrument Co., Ltd. Centrifuge TG16-W, Hunan Xiangyi Laboratory Instrument Development Co., Ltd.

1.2试验方法1.2 Test method

1.2.1腹泻犊牛粪便大肠杆菌k99进行细菌分离鉴定1.2.1 Bacterial isolation and identification of Escherichia coli k99 from feces of calves with diarrhea

采用棉拭子无菌采集四个某规模化牛场7日龄以内腹泻的犊牛采集腹泻粪样,通过在无菌生理盐水中稀释并在LB肉汤培养基中进行37℃培养,进一步在LB固体培养基中纯化,并分离纯化,革兰氏染色之后镜检,对纯化菌落进行-80℃保存,同时采用试剂盒提取纯化细菌的DNA,采用大肠杆菌k99特异性引物(5’-TATTATCTGGTGGTATGG-3’,5’-GGTATCCTTTAGCAGCAGTATTTC-3’)进行PCR扩增,PCR反应体系和反应条件为:采用20uL反应体系:2×master PCR Mix lOuL,DNA模板3uL、上下游引物各0.5uL(引物浓度为20umol/L),加灭菌超纯水至20uL。94℃5min预变性;94℃、30s变性;52.6℃、30s退火;72℃、30s延伸;循环35次,72℃延伸10min。对扩增产物进行回收并进行测序,同时对大肠杆菌K99菌株进行生理生化鉴定。Using cotton swabs to aseptically collect diarrhea fecal samples from four calves with diarrhea within 7 days of age in a large-scale cattle farm, dilute in sterile saline and culture in LB broth medium at 37 °C, and further in Purified in LB solid medium, and separated and purified. After Gram staining, microscopic examination was performed, and the purified colonies were stored at -80 °C. At the same time, the DNA of bacteria was extracted and purified by a kit, and the specific primer (5'-TATTATCTGGTGGTATGG) of Escherichia coli k99 was used. -3', 5'-GGTATCCTTTAGCAGCAGTATTTC-3') for PCR amplification, the PCR reaction system and reaction conditions are: 20uL reaction system: 2×master PCR Mix 10uL, DNA template 3uL, upstream and downstream primers each 0.5uL (primer concentration 20umol/L), add sterile ultrapure water to 20uL. Pre-denaturation at 94°C for 5 min; denaturation at 94°C for 30s; annealing at 52.6°C for 30s; extension at 72°C for 30s; cycle 35 times, extension at 72°C for 10min. The amplified product was recovered and sequenced, and the physiological and biochemical identification of Escherichia coli K99 strain was carried out.

1.2.2菌种的活化和活菌含量测定1.2.2 Activation of strains and determination of viable bacterial content

菌株活化:将3种菌株接种于相应的液体培养基中37℃摇床培养18h使用接种环在MRS固体培养基、YPD固体培养基、芽孢杆菌培养基中涂面和划线,挑取单个菌株接种到MRS肉汤培养基、YPD肉汤培养基、芽孢杆菌肉汤培养基中,其中嗜酸乳杆菌于37℃培养静置培养24h,布拉迪酵母菌和枯草芽孢杆菌37℃培养静置培养24h,活化2-3代,备用。Strain activation: Inoculate the 3 strains in the corresponding liquid medium at 37°C for 18h in a shaker, use the inoculation loop to coat and streak in MRS solid medium, YPD solid medium, and Bacillus medium, pick a single strain Inoculated into MRS broth, YPD broth, and Bacillus broth, where Lactobacillus acidophilus was cultured at 37°C for 24 hours, and Saccharomyces cerevisiae and Bacillus subtilis were cultured at 37°C. Cultivated for 24h, activated for 2-3 generations, and set aside.

活菌含量测定:无菌条件下,将活化2代的益生菌(嗜酸乳杆菌,枯草芽孢杆菌,布拉迪酵母菌、大肠杆菌)进行梯度稀释,将悬浊液10倍倍比稀释至10-7、10-8、10-9,然后取三个稀释度的菌液各100uL进行平板涂布,每个稀释度涂布三个平板,37℃倒置培养12-24h后,进行菌落计数。Determination of viable bacteria content: Under sterile conditions, the activated probiotics of the second generation (Lactobacillus acidophilus, Bacillus subtilis, Saccharomyces boulardii, Escherichia coli) were serially diluted, and the suspension was diluted 10 times to 10 -7 , 10 -8 , 10 -9 , then take 100uL of each of the three dilutions of bacterial liquid for plate coating, spread three plates for each dilution, and invert at 37 °C for 12-24h After culturing for 12-24 hours, count the colonies .

1.2.3三种益生菌不同pH值耐受性试验1.2.3 Tolerance test of three probiotics at different pH values

人工胃液制备:取质量分数为0.1kg/L的盐酸16.4mL,将其pH值调至2.0、3.0、4.0、5.0、6.0。然后加入胃蛋白酶,比例为0.01g/mL,待其溶解均匀后,微孔滤膜除菌,备用。将已经活化的嗜酸乳杆菌、嗜酸乳杆菌、布拉迪酵母菌、枯草芽孢杆菌按照1%接种比例接种到上述不同PH值的胃蛋白酶溶液中,37℃恒温培养箱中培养3h,测定OD600Preparation of artificial gastric juice: take 16.4 mL of hydrochloric acid with a mass fraction of 0.1 kg/L, and adjust its pH to 2.0, 3.0, 4.0, 5.0, and 6.0. Then, pepsin was added at a ratio of 0.01 g/mL, and after it was evenly dissolved, the microporous membrane was sterilized and used for later use. The activated Lactobacillus acidophilus, Lactobacillus acidophilus, Saccharomyces boulardii, and Bacillus subtilis were inoculated into the above pepsin solutions with different pH values according to the inoculation ratio of 1%, and cultivated in a constant temperature incubator at 37 °C for 3 hours. OD600 .

1.2.4人工肠液耐受性试验1.2.4 Tolerance test of artificial intestinal fluid

人工肠液制备:准确称取KH2P043.4g,加蒸馏水250mL溶解,用质量分数4g/L NaOH溶液调pH至6.8,加入胃蛋白酶,使其浓度为0.01g/mL,待其溶解均匀后,微孔滤膜除菌,置于4℃冰箱备用。将活化后的3株益生菌菌株分别以10%接种量接入到上述人工肠液中,每个处理重复3次,37℃培养,分别在0、3、6、9小时取样,用酶标仪测定各菌株的OD600值。Preparation of artificial intestinal juice: accurately weigh 3.4 g of KH 2 P0 4 , add 250 mL of distilled water to dissolve, adjust the pH to 6.8 with a mass fraction of 4 g/L NaOH solution, add pepsin to make its concentration 0.01 g/mL, and wait for it to dissolve evenly. , sterilized by a microporous filter, and placed in a 4°C refrigerator for later use. The three activated probiotic strains were added to the above artificial intestinal fluid with 10% inoculum respectively, and each treatment was repeated 3 times, cultured at 37°C, and sampled at 0, 3, 6, and 9 hours, respectively, with a microplate reader. The OD 600 value of each strain was determined.

1.2.5胆盐耐受性试验1.2.5 Bile salt tolerance test

分别向MRS、YPD、芽孢杆菌液体培养基中添加牛胆盐,使其配制成牛胆盐浓度分别为0.15g/L、0.3g/L和0.06g/L的培养基。然后将3种培养基在118℃的条件下灭菌15分钟,冷却之后备用。把上述己活化菌种分别接种到上述配制的相应牛胆盐培养基中,以未加胆盐的培养基作参照,37℃的恒温条件下培养8h,观察菌种的生长情况,测OD600,计算存活率。Bovine bile salts were added to MRS, YPD and Bacillus liquid medium respectively to prepare the medium with bovine bile salt concentrations of 0.15g/L, 0.3g/L and 0.06g/L respectively. The three media were then sterilized at 118°C for 15 minutes, and then used after cooling. The above-mentioned activated strains were inoculated into the corresponding bovine bile salts medium prepared above, and the medium without bile salts was used as a reference, and cultivated for 8h at a constant temperature of 37 ° C to observe the growth of the strains, and measure the OD 600 , to calculate the survival rate.

1.2.6抑菌性试验1.2.6 Bacteriostatic test

将分离的大肠杆菌k99、沙门氏菌、金黄色葡萄球菌分别培养24h,按20倍稀释,取100uL致病菌液均匀涂布到事先准备好的无菌琼脂平板上。采用牛津杯及打孔发法,37℃培养12-24h,测定抑菌圈直径,以无菌普通液体培养基作对照。The isolated Escherichia coli k99, Salmonella, and Staphylococcus aureus were cultured for 24h respectively, diluted 20 times, and 100uL of the pathogenic bacteria solution was evenly spread on the sterile agar plate prepared in advance. Using Oxford cup and punching method, cultured at 37°C for 12-24h, the diameter of inhibition zone was measured, and sterile common liquid medium was used as control.

1.2.73株菌种抑制大肠杆菌k99的配比优化1.2.73 strains to inhibit Escherichia coli k99 ratio optimization

将活化好的3株益生菌,稀释为10-1的稀释悬液。然后再将稀释至相同浓度(1×109cfu/mL),按照表1中种不同配比比例进行接种,并设置对照组,共11组,分别加入到一定量的LB液体培养基中,使其终体积为5mL,于37℃,165rpm进行摇床培养。培养时间设置为12h和24h。之后进行梯度稀释,取10-6、10-7、10-7100uL涂布麦康凯琼脂培养基中,于37℃恒温培养箱中培养24h后进行大肠杆菌计数,同时设定对照组。Dilute the activated 3 strains of probiotics into a 10 -1 dilution suspension. Then it was diluted to the same concentration (1×10 9 cfu/mL), inoculated according to the different proportions of the species in Table 1, and a control group was set up, a total of 11 groups were added to a certain amount of LB liquid medium, respectively. The final volume was 5 mL, and the culture was shaken at 37°C and 165 rpm. The incubation time was set to 12h and 24h. Then carry out gradient dilution, take 10 -6 , 10 -7 , 10 -7 100uL to spread on MacConkey agar medium, culture in a constant temperature incubator at 37°C for 24 hours, and count E. coli, and set a control group at the same time.

表1三种益生菌不同配比的接种量单位:uLTable 1 The inoculum unit of different proportions of three kinds of probiotics: uL

Figure BDA0002593421390000061
Figure BDA0002593421390000061

Figure BDA0002593421390000071
Figure BDA0002593421390000071

1.2.8检测指标:1.2.8 Detection indicators:

检测OD600值及大肠杆菌K99活菌数。The OD 600 value and the viable count of Escherichia coli K99 were detected.

1.2.9数据分析:1.2.9 Data Analysis:

试验数据采用Spss21.0统计软件对单因素方差分析(ONE-WAY ANONA)和Duncan氏多重分析,结果用“平均值士标准差”表示,P<0.05为差异显著。The test data were analyzed by one-way analysis of variance (ONE-WAY ANONA) and Duncan's multiple analysis using Spss21.0 statistical software.

2.结果与分析2. Results and Analysis

2.1腹泻犊牛粪便大肠杆菌k99进行细菌分离鉴定2.1 Bacterial isolation and identification of Escherichia coli k99 from feces of calves with diarrhea

大肠杆菌纯化菌落经革兰氏染色,镜检为G-,短杆状,结果如图1所示,大肠杆菌k99扩增图2;在NCBI Genbank进行BLAST,结果显示相似度为99.99%,如图3所示。生化鉴定如表2所示。The purified E. coli colonies were Gram-stained, and the microscopic examination was G - , short rod-shaped, the results are shown in Figure 1, and E. coli k99 was amplified in Figure 2; BLAST was performed on NCBI Genbank, and the results showed that the similarity was 99.99%, as shown in Figure 3. The biochemical identification is shown in Table 2.

同时采用分离的大肠杆菌k99对小鼠进行攻毒,每小鼠注射0.2mL培养18小时的大肠杆菌菌液,结果显示80%小鼠死亡。证明分离的大肠杆菌k99具有较强的毒力。At the same time, the isolated Escherichia coli k99 was used to challenge the mice, and each mouse was injected with 0.2 mL of Escherichia coli bacteria cultured for 18 hours. The results showed that 80% of the mice died. It is proved that the isolated E. coli k99 has strong virulence.

表2大肠杆菌k99生理生化鉴定表Table 2 Physiological and biochemical identification of Escherichia coli k99

Figure BDA0002593421390000072
Figure BDA0002593421390000072

Figure BDA0002593421390000081
Figure BDA0002593421390000081

2.2三种益生菌不同pH值耐受性试验2.2 Tolerance test of three probiotics at different pH values

试验果如图4-6所示,三种益生菌在不同pH值培养条件下都具有较好的耐受性,其中嗜酸乳杆菌在pH为5时,存活率达到了118.75%,在pH为3时,存活率为84.34%。The test results are shown in Figure 4-6. The three probiotics have good tolerance under different pH values. Among them, Lactobacillus acidophilus has a survival rate of 118.75% at pH 5. When it was 3, the survival rate was 84.34%.

布拉迪酵母菌对不同pH值均表现成活率达到了100%以上。芽孢杆菌在pH为5时,存活率为142.24%,在不同的pH条件下,存活率均达到了100%以上,具有较好的耐受性。Saccharomyces boulardii showed a survival rate of more than 100% at different pH values. When the pH of Bacillus is 5, the survival rate is 142.24%, and under different pH conditions, the survival rate reaches more than 100%, and has good tolerance.

2.3三种益生菌人工肠液耐受性试验2.3 Tolerance test of three kinds of probiotics in artificial intestinal fluid

结果如图7所示,三种益生菌对人工肠液在不同的培养时间下具有较好的耐受性,三种益生菌在人工胃液中9小时存活率都很高,与0小时的OD600相比,布拉迪酵母菌和嗜酸乳杆存活率分别为108.7%、129.73%,嗜酸乳杆菌达到了96.37%。The results are shown in Figure 7. The three probiotics have good tolerance to artificial intestinal juice at different incubation times, and the three probiotics have a high survival rate in artificial gastric juice at 9 hours, which is comparable to the OD 600 of 0 hours. In contrast, the survival rates of Saccharomyces boulardii and Lactobacillus acidophilus were 108.7% and 129.73%, respectively, and Lactobacillus acidophilus reached 96.37%.

2.4三种益生菌胆盐耐受性试验2.4 Bile salt tolerance test of three probiotics

结果如图8所示:随着牛胆盐浓度的提高,布拉迪酵母菌存活率较对照组的存活率分别为50.64%、60.49%、46.37%,嗜酸乳杆菌存活率较对照组分别为81.65%、85.1%、81.19%,芽孢杆菌存活率较对照组的存活率分别为45.1%、45.11%、47.42%。布拉迪酵母菌和嗜酸乳杆菌对牛胆盐的耐受能力较强,而芽孢杆菌较弱。The results are shown in Figure 8: with the increase of bovine bile salt concentration, the survival rate of Saccharomyces boulardii was 50.64%, 60.49%, and 46.37% compared with the control group, and the survival rate of Lactobacillus acidophilus was higher than that of the control group, respectively. were 81.65%, 85.1%, and 81.19%, and the survival rate of Bacillus was 45.1%, 45.11%, and 47.42%, respectively, compared with the control group. Saccharomyces boulardii and Lactobacillus acidophilus were more resistant to bovine bile salts, while Bacillus was weaker.

2.5三种益生菌的抑菌性试验2.5 Bacteriostatic test of three probiotics

结果如表3所示,布拉迪酵母菌、嗜酸乳杆菌、芽孢杆菌、对大肠杆菌、沙门氏菌均有一定的抑菌特性,嗜酸乳杆菌对金黄色葡萄球菌的抑菌性较强,布拉迪酵母菌、嗜酸乳杆菌对金黄色葡萄球菌抑菌性较差。The results are shown in Table 3. Saccharomyces boulardii, Lactobacillus acidophilus, Bacillus, Escherichia coli and Salmonella have certain antibacterial properties, and Lactobacillus acidophilus has strong antibacterial properties against Staphylococcus aureus. Saccharomyces boulardii and Lactobacillus acidophilus have poor bacteriostatic activity against Staphylococcus aureus.

表3三种益生菌的抑菌圈直径Table 3 Diameter of inhibition zone of three probiotics

Figure BDA0002593421390000091
Figure BDA0002593421390000091

2.6三株菌种抑制大肠杆菌k99的配比优化2.6 Optimization of the ratio of three strains to inhibit Escherichia coli k99

嗜酸乳杆菌、布拉迪酵母菌、芽孢杆菌按不同配比组合,在培养12h、24h后对牛源大肠杆菌K99的体外抑菌试验结果如表4所示。Table 4 shows the results of the in vitro antibacterial test of Lactobacillus acidophilus, Saccharomyces bovis, and Bacillus in different proportions to bovine Escherichia coli K99 after culturing for 12h and 24h.

表4三种益生菌制剂按不同配比对大肠杆菌k99的体外抑菌试验(n=3)logcfu/mLTable 4 In vitro antibacterial test of three kinds of probiotic preparations according to different ratios to Escherichia coli k99 (n=3) logcfu/mL

Figure BDA0002593421390000092
Figure BDA0002593421390000092

同行无字母或数据肩标相同字母,表示差异不显著(P>0.05),不同小写字母表示差异显著(P<0.05)。下表同。If there is no letter in the same line or the data with the same letter, it means that the difference is not significant (P>0.05), and different lowercase letters means the difference is significant (P<0.05). The table below is the same.

从表4可以看出,三种益生菌按照不同配比在培养12h后,试验组第1、2、3、4、5、6、7、8、9组较对照组相比差异显著(P<0.05),第10组与对照组相比差异不显著(P>0.05),第1、3、5、6、7、9、10组之间差异不显著(P>0.05),与第2、4、8组之间差异显著(P<0.05);在培养24h后,试验组第2、3、4、5、6、8较对照组相比差异显著(P<0.05),但第2、3、4、5、6、8之间差异不显著(P>0.05),试验组第1、2、7、9、10组较对照组相比差异不显著(P>0.05)。It can be seen from Table 4 that after culturing the three probiotics in different proportions for 12 hours, the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, and 9th groups of the experimental group were significantly different from those of the control group (P <0.05), there was no significant difference between the 10th group and the control group (P>0.05), and there was no significant difference between the 1st, 3rd, 5th, 6th, 7th, 9th and 10th groups (P>0.05). , 4 and 8 groups were significantly different (P<0.05); after 24 hours of culture, the 2, 3, 4, 5, 6 and 8 of the experimental group were significantly different from those of the control group (P<0.05), but the second, , 3, 4, 5, 6, and 8 were not significantly different (P>0.05), and the first, 2, 7, 9, and 10 groups in the experimental group had no significant differences compared with the control group (P>0.05).

综上,结合实际应用中,牛肠道蠕动12h后复合微生物制剂被排出,第8个处理组在培养12h后对大肠杆菌K99的抑菌效果较好,从而可以确定嗜酸乳杆菌、枯草芽孢杆菌、布拉迪酵母菌最佳的复配比例为3:3:1。In summary, combined with the practical application, the composite microbial preparation was discharged after 12 hours of peristalsis in the bovine intestinal tract, and the eighth treatment group had better bacteriostatic effect on E. The optimal compounding ratio of Bacillus and Saccharomyces bodrum is 3:3:1.

益生菌的益生特性分析:Analysis of the probiotic properties of probiotics:

由于本研究是针对犊牛大肠杆菌K99研究复合益生菌,所以根据初生犊牛的消化系统发育不完善特点,主要依靠皱胃和小肠来消化吸收日粮中的营养物质,并且在两周龄以内的犊牛不出现反刍行为,其消化功能的特征基本上类似于单胃动物,而此时犊牛的消化道酸度pH值波动较大,对其消化生理具有较大的影响,研究表明犊牛进食前后皱胃pH值24h变化较大,犊牛在饲喂前皱胃pH值在1.5-2.0之间,饲喂之后皱胃pH值可以从1.5升高到6.0,之后又会降低到1.5-2.0之间,可见犊牛的皱胃pH在进食前后波动较大,但随着进食时间也会呈现稳定的状态。犊牛不同肠断中胰蛋白酶也有所不同,其中十二指肠中活性最低,空肠最高,回肠次之。犊牛肠道内胆汁浓度是不断变化的,因而很难预测其在某一时间段内的浓度,但总的来说,小肠中胆盐含量通常在0.03-0.3%。Since this study is aimed at calf Escherichia coli K99 to study compound probiotics, according to the characteristics of the immature digestive system of newborn calves, the abomasum and small intestine mainly rely on the abomasum and small intestine to digest and absorb nutrients in the diet, and within two weeks of age The calf does not appear ruminant behavior, and the characteristics of its digestive function are basically similar to those of monogastric animals. At this time, the acidity and pH value of the calf's digestive tract fluctuates greatly, which has a greater impact on its digestive physiology. Studies have shown that calves The pH value of the abomasum changes greatly before and after eating for 24 hours. The pH value of the abomasum of calves before feeding is between 1.5 and 2.0. Between 2.0, it can be seen that the pH of the calf's abomasum fluctuates greatly before and after eating, but it also shows a stable state with the time of eating. The levels of trypsin in different intestinal breaks of calves are also different, the activity of which is the lowest in the duodenum, the highest in the jejunum, and the second in the ileum. The intestinal bile concentration of calves is constantly changing, making it difficult to predict its concentration over a period of time, but in general, bile salts in the small intestine are typically 0.03-0.3%.

而益生菌体外鉴定已广泛应用于评价候选菌的益生菌潜能。包括对胃液和胆盐含量的耐受性、抗菌作用等。益生菌能够在动物机体存活的一个重要特征是其耐受胃的酸性条件和小肠中胆汁盐能力。In vitro identification of probiotics has been widely used to evaluate the probiotic potential of candidate bacteria. Including tolerance to gastric juice and bile salt content, antibacterial effect, etc. An important feature of probiotics' survival in animals is their ability to tolerate the acidic conditions of the stomach and bile salts in the small intestine.

本实验结果表明三株益生菌嗜酸乳杆菌、芽孢杆菌、布拉迪酵母菌对酸性条件、牛胆盐、胰蛋白酶的均具有较高的耐受性。The results of this experiment showed that the three probiotic strains Lactobacillus acidophilus, Bacillus and Saccharomyces bradii had high tolerance to acidic conditions, bovine bile salts and trypsin.

嗜酸乳杆菌、枯草芽孢杆菌、布拉迪酵母菌不同配比对大肠杆菌(K99)的抑菌作用:The antibacterial effects of different ratios of Lactobacillus acidophilus, Bacillus subtilis, and Saccharomyces bollardii on Escherichia coli (K99):

饲用微生物添加剂为一种活性制剂,由于具有绿色、无污染,在促进动物生长、肠道健康等方面的应用取得了前所未有的发展,在操纵宿主的健康轨迹(包括和超越免疫成分)中起着很大的作用,且具有促进营养物质吸收、调节肠道菌群结构及提高畜禽机体免疫力等生物学功能。Feed microbial additive is an active formulation that has achieved unprecedented development in applications in promoting animal growth, intestinal health, etc. due to its green and non-polluting properties, playing a role in manipulating the host's health trajectory (including and beyond immune components) It plays a great role, and has biological functions such as promoting the absorption of nutrients, regulating the structure of intestinal flora and improving the immunity of livestock and poultry.

嗜酸乳杆菌是一种典型的益生菌,具有抑制肠道病原体、促进免疫细胞的稳态及肠道健康、具有抑制产肠毒素大肠杆菌K99的作用等生理作用。有研究表明嗜酸乳杆菌菌在菌株在pH 3中存活率较高、含有胆盐的培养基中具有较强的生存能力,且临界浓度为0.3%,表明该菌株在通过小肠时具有抵抗其抗菌作用的能力。Lactobacillus acidophilus is a typical probiotic with physiological functions such as inhibiting intestinal pathogens, promoting immune cell homeostasis and intestinal health, and inhibiting enterotoxin-producing Escherichia coli K99. Studies have shown that Lactobacillus acidophilus has a high survival rate in pH 3 and medium containing bile salts, and the critical concentration is 0.3%, indicating that the strain has resistance to its passage through the small intestine. Antibacterial ability.

布氏酵母菌是急性胃肠炎(AGE)中研究得最好的益生菌之一,被证明是安全的。布拉迪酵母菌具有抗毒素,布拉迪酵母菌分泌的磷酸酶可以显著破坏大肠杆菌分泌的内毒素。对鼠伤寒沙门氏杆菌、大肠杆菌、白色念球菌等具有抑制生长的作用,它能够提高机体肠道内短链脂肪酸的活性,调节肠道的代谢功能,促进肠道粘膜的营养效应,增强机体的免疫功能,防治病原性感染的作用增加机体SCFA的含量。由于它是好氧菌,并且具有较高的粘附性,能够消耗肠道内的氧气同时分解过氧化氢,促进厌氧菌的增值,并且能够调节因抗生素使用不当而引起的菌群失衡,从而促进肠道菌群平衡。在家禽、猪、水产上应用研究已有相关报道,但是在反刍动物尤其是犊牛上的研究较少。在犊牛上应用具有增加犊牛日增重,降低腹泻率,提高免疫力等作用。Brucella is one of the best-studied probiotics in acute gastroenteritis (AGE) and has been shown to be safe. Saccharomyces boulardii is antitoxin, and the phosphatase secreted by Saccharomyces boulardii can significantly destroy the endotoxin secreted by Escherichia coli. It has the effect of inhibiting the growth of Salmonella typhimurium, Escherichia coli, Candida albicans, etc. It can improve the activity of short-chain fatty acids in the intestinal tract of the body, regulate the metabolic function of the intestinal tract, promote the nutritional effect of the intestinal mucosa, and enhance the body's The role of immune function, prevention and treatment of pathogenic infection increases the content of SCFA in the body. Because it is aerobic and has high adhesion, it can consume oxygen in the intestines and decompose hydrogen peroxide, promote the growth of anaerobic bacteria, and regulate the imbalance of flora caused by improper use of antibiotics, thereby Promotes intestinal flora balance. There have been relevant reports on applied research on poultry, pigs, and aquaculture, but less research has been done on ruminants, especially calves. Application on calves can increase the daily weight gain of calves, reduce the rate of diarrhea, and improve immunity.

枯草芽抱杆菌在动物机消化道内的含量较少。由于其实耗氧菌,能够快速消耗动物消化道内的氧气,使其产生厌氧的环境,抑制有害致病菌的生长。同时,芽抱杆菌具有杀菌作用,其产生的代谢产物中的细菌素能够有效的杀灭大肠杆菌、金黄色葡萄球菌和沙门氏菌等病原性菌群,从而维持动物机体的健康。The content of Bacillus subtilis in the digestive tract of animals is less. In fact, aerobic bacteria can quickly consume oxygen in the digestive tract of animals, creating an anaerobic environment and inhibiting the growth of harmful pathogenic bacteria. At the same time, Bacillus has bactericidal effect, and the bacteriocin in its metabolites can effectively kill pathogenic flora such as Escherichia coli, Staphylococcus aureus and Salmonella, thereby maintaining the health of the animal body.

在本试验中,通过对分离鉴定腹泻犊牛粪便中致病性大肠杆菌,对嗜酸乳杆菌、布拉迪酵母菌、枯草芽孢杆菌3株益生菌在耐酸性、耐胆盐及抑菌性生物学特性比较分析发现,三株益生菌均具有较好的耐受性,并通过对三株益生菌的不同配比抑制大肠杆菌k99发现,确定嗜酸乳杆菌、枯草芽孢杆菌、布拉迪酵母菌最佳的复配比例为3:3:1时具有较好的抑菌效果,可用于后期开发替代抗生素、预防幼龄犊牛消化道疾病提供理论基础。In this experiment, through the isolation and identification of pathogenic Escherichia coli in the feces of calves with diarrhea, the three probiotic bacteria strains of Lactobacillus acidophilus, Saccharomyces bollardii, and Bacillus subtilis have the acid resistance, bile salt resistance and bacteriostatic activity. The comparative analysis of biological characteristics found that the three probiotics had good tolerance, and by inhibiting Escherichia coli k99 with different ratios of the three probiotics, Lactobacillus acidophilus, Bacillus subtilis, Brady When the optimal compounding ratio of yeast is 3:3:1, it has a good bacteriostatic effect, which can be used for the later development of alternative antibiotics and to provide a theoretical basis for the prevention of digestive tract diseases in young calves.

二微生态制剂对犊牛生长性能、腹泻率、血液免疫指标和抗氧化性能的影响Effects of two microecological preparations on growth performance, diarrhea rate, blood immune indexes and antioxidant properties of calves

试验选用5日龄犊牛40头,随机分为4组,每组10头,每个重复1头牛。Ⅰ组为对照组,饲喂等量的生理盐水,Ⅱ组饲喂微生物制剂0.5g,Ⅲ组饲喂微生物制剂1g,Ⅳ组饲喂微生物制剂2g,验期为8周,分别与试验开始第0、2、4、6、8周采集试验数据。以生长性能、腹泻率、血液免疫指标和抗氧化性能作为评价指标。40 5-day-old calves were selected for the experiment and randomly divided into 4 groups with 10 calves in each group and 1 calf in each replicate. Group I was the control group, fed the same amount of normal saline, group II was fed 0.5 g of microbial preparations, group III was fed 1 g of microbial preparations, and group IV was fed 2 g of microbial preparations. The experimental data were collected at 0, 2, 4, 6, and 8 weeks. Growth performance, diarrhea rate, blood immune index and antioxidant performance were used as evaluation indicators.

微生物制剂为表4中的第8个微生物制剂。The microbial preparation was the eighth microbial preparation in Table 4.

(一)试验方法和数据采集(1) Test method and data collection

1、生长性能、采食量、粪便评分1. Growth performance, feed intake, stool score

(1)采食量:每天记录犊牛代乳品、开食料和苜蓿的采食量。(1) Feed intake: The feed intake of calf milk replacer, starter and alfalfa was recorded every day.

(2)粪便评分:根据评分标准(表)评估试验犊牛粪便情况。1分,正常形状;2分,软并松散;3分,松散呈水样;4分,水样、粘液、少量血丝;5分,水样、粘液、大量血丝。当粪便被评为3分及以上时记为腹泻。(2) Feces score: Evaluate the feces of the test calves according to the scoring standard (table). 1 point, normal shape; 2 points, soft and loose; 3 points, loose and watery; 4 points, watery, mucus, a little blood; 5 points, watery, mucus, a lot of blood. Diarrhea was recorded when stool was rated 3 and above.

腹泻率(%)=Σ(腹泻头数×腹泻天数)/(总头数×试验天数)×100。Diarrhea rate (%) = Σ (diarrhea head count×diarrhea days)/(total head count×test days)×100.

2、血清样品采集与测定2. Serum sample collection and determination

与饲养第2、4、6、周龄当天晨饲前用含肝素钠的真空采血管颈静脉采血5mL,室温下静置30min,然后3000r/min离心15min,取血清装入1.5mL的冻存管中,标注组别及牛号,采样日期,液氮保存。测血清中Ig A、Ig G、Ig M、IL-2、IL-4、IL-1β和TNF-α的浓度,测定血清总蛋白((TP)、球蛋白(Glb)、白蛋白(Alb)、葡萄糖(Glu),尿素氮(BUN)、碱性磷酸酶(ALP)、肌酐、谷草转氨酶(AST)及谷丙转氨酶(ALT)浓度。5 mL of blood was collected from the jugular vein with a vacuum blood collection tube containing heparin sodium before the morning feeding on the 2nd, 4th, 6th, and 6th weeks of feeding, and left standing at room temperature for 30 minutes, then centrifuged at 3000 r/min for 15 minutes, and the serum was collected into 1.5 mL of cryopreservation. In the tube, mark the group and cattle number, sampling date, and store in liquid nitrogen. Measure the concentrations of Ig A, IgG, Ig M, IL-2, IL-4, IL-1β and TNF-α in serum, and measure serum total protein ((TP), globulin (Glb), albumin (Alb) , glucose (Glu), urea nitrogen (BUN), alkaline phosphatase (ALP), creatinine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations.

3、粪样采集:3. Fecal sample collection:

(1)液氮冻存粪样:分别于犊牛0、2、4、6、8周龄晨饲前采集粪样置于50ml离心管中,每组随机选取6头牛直肠取粪,每头牛采集的粪样分装6个小管。液氮冻存。(1) Liquid nitrogen cryopreservation of fecal samples: fecal samples were collected before morning feeding of calves at 0, 2, 4, 6, and 8 weeks of age and placed in 50ml centrifuge tubes. Six cows were randomly selected from each group to collect feces from the rectum. The fecal samples collected from the head cows were divided into 6 small tubes. Freeze in liquid nitrogen.

4、血液免疫指标和抗氧化性能4. Blood immune indexes and antioxidant properties

采用试剂盒检测。Tested with a kit.

(二)结果:(2) Results:

1、复合益生菌对犊牛生长性能的影响1. The effect of compound probiotics on the growth performance of calves

如表5所示,在第2周,试验组Ⅲ的平均日增重高于对照组Ⅰ,差异有显著性(P<0.05),但各组间无显著性差异(P>0.05)。Ⅱ、Ⅲ、Ⅳ组平均日采食量高于Ⅰ组(P<0.05),但各组间差异无显著性(P>0.05)。4wk时,各组间的平均日增重和平均日采食量无显著性差异(P>0.05)。6wk时,Ⅱ、Ⅲ组日增重显著高于Ⅰ、Ⅳ组(P<0.05),Ⅱ、Ⅳ组与Ⅰ组比较差异有显著性(P<0.05)。8wk时,各组间ADG无显著性差异(P>0.05),但Ⅱ、Ⅳ组ADG高于Ⅰ组。与Ⅰ、Ⅱ、Ⅲ组比较,Ⅳ组的admi有显著性差异(P<0.05),而Ⅱ组与Ⅲ组之间无显著性差异(P>0.05)。As shown in Table 5, in the second week, the average daily weight gain of the experimental group III was higher than that of the control group I, and the difference was significant (P<0.05), but there was no significant difference between the groups (P>0.05). The average daily feed intake of group Ⅱ, Ⅲ and Ⅳ was higher than that of group Ⅰ (P<0.05), but there was no significant difference between groups (P>0.05). At 4wk, there was no significant difference in the average daily gain and average daily feed intake among the groups (P>0.05). At 6wk, the daily weight gain of Ⅱ and Ⅲ groups was significantly higher than that of Ⅰ and Ⅳ groups (P<0.05). At 8wk, there was no significant difference in ADG among the groups (P>0.05), but the ADG in groups Ⅱ and Ⅳ was higher than that in group Ⅰ. Compared with group Ⅰ, Ⅱ, Ⅲ, the admi of group Ⅳ had significant difference (P<0.05), but there was no significant difference between group Ⅱ and group Ⅲ (P>0.05).

表5复合微生态制剂对犊牛生长性能的影响Table 5 Effects of compound probiotics on growth performance of calves

Figure BDA0002593421390000131
Figure BDA0002593421390000131

在同一行中,标注不同小写字母表示差异有显著性(P<0.05),相同或无字母上标均无显著性差异(P>0.05),下同。ADG(平均日增重)、ADMI(日均采食量)。In the same row, different lowercase letters indicate significant differences (P < 0.05), and there is no significant difference with the same or no superscript letters (P > 0.05), the same below. ADG (average daily gain), ADMI (average daily feed intake).

2、复合益生菌对犊牛粪便评分和腹泻率的影响2. The effect of compound probiotics on calf fecal score and diarrhea rate

表6复合微生态制剂对犊粪便评分和腹泻率的影响Table 6 Effects of compound probiotics on calf manure score and diarrhea rate

Figure BDA0002593421390000141
Figure BDA0002593421390000141

从表6可以看出,粪便评分在2WK和4WK时,Ⅰ、Ⅱ、Ⅲ组粪便评分组间无显著性差异(P>0.05),Ⅱ、Ⅳ组粪便评分组间无显著性差异(P>0.05),Ⅰ、Ⅲ组较Ⅳ粪便评分组间显著性差异显著(P<0.05);在6WK和8WK时,各组组之间差异不显著(P>0.05)。It can be seen from Table 6 that there was no significant difference in stool score between groups I, II and III at 2WK and 4WK (P>0.05), and there was no significant difference between groups II and IV (P>0.05). 0.05), there were significant differences between groups Ⅰ and Ⅲ compared with group Ⅳ stool score (P<0.05); at 6WK and 8WK, there was no significant difference between groups (P>0.05).

在2WK和4WK时,试验组较对照组的腹泻率有所降低,在2WK时,Ⅳ组较Ⅰ组降低了51.65%,在4WK时,Ⅳ组腹泻率为0。At 2WK and 4WK, the diarrhea rate in the experimental group was lower than that in the control group. At 2WK, the rate of diarrhea in group IV decreased by 51.65% compared with group I. At 4WK, the diarrhea rate in group IV was 0.

3、复合益生菌对哺乳犊牛免疫功能的影响3. The effect of compound probiotics on the immune function of lactating calves

如表7所示,不同周龄犊牛血清中IgA含量不同。第2周时,Ⅱ、Ⅳ差异显著(P<0.05),Ⅲ、Ⅳ显著高于Ⅰ(P<0.05);第4周,Ⅲ、Ⅳ差异极显著(P<0.001),Ⅱ、Ⅲ差异显著(P<0.05),Ⅰ、Ⅱ差异不显著(P>0.05)0.05),Ⅲ、Ⅳ间差异显著(P<0.001),Ⅱ、Ⅲ差异显著(P<0.05),Ⅰ、Ⅱ差异不显著(P>0.05),Ⅲ、Ⅳ之间差异不显著(P>0.05);6wk时,Ⅱ、Ⅳ组间差异极显著(P<0.05)(P<0.001),Ⅲ与Ⅰ、Ⅱ差异显著(P<0.05),Ⅳ与Ⅰ、Ⅱ差异显著(P<0.001);8wk时,Ⅳ与Ⅰ差异显著(P<0.05),Ⅰ、Ⅱ、Ⅲ无显著性差异(P>0.05)。As shown in Table 7, the content of IgA in the serum of calves of different ages was different. At the second week, the difference between II and IV was significant (P<0.05), and III and IV were significantly higher than I (P<0.05); at the fourth week, the difference between III and IV was extremely significant (P<0.001), and the difference between II and III was significant. (P<0.05), there was no significant difference between I and II (P>0.05) 0.05), there was a significant difference between III and IV (P<0.001), and the difference between II and III was significant (P<0.05), and the difference between I and II was not significant (P<0.05). P>0.05), there was no significant difference between Ⅲ and Ⅳ (P>0.05); at 6wk, the difference between Ⅱ and Ⅳ groups was extremely significant (P<0.05) (P<0.001), and the difference between Ⅲ and Ⅰ, Ⅱ was significant (P<0.001). <0.05), there was significant difference between IV and I, II (P<0.001); at 8wk, IV and I were significantly different (P<0.05), and I, II, III had no significant difference (P>0.05).

不同周龄犊牛血清IgM水平不同。第2周时,Ⅱ、Ⅳ差异显著(P<0.05),Ⅲ、Ⅳ显著高于Ⅰ(P<0.05);第4周,Ⅲ、Ⅳ差异极显著(P<0.001),Ⅱ、Ⅲ差异显著(P<0.05),Ⅰ、Ⅱ差异不显著(P>0.05)0.05),Ⅲ、Ⅳ间差异显著(P<0.001),Ⅱ、Ⅲ差异显著(P<0.05),Ⅰ、Ⅱ差异不显著(P>0.05),Ⅲ、Ⅳ之间差异不显著(P>0.05);6wk时,Ⅱ、Ⅳ组间差异极显著(P<0.05)(P<0.001),Ⅲ与Ⅰ、Ⅱ差异显著(P<0.05),Ⅳ与Ⅰ、Ⅱ差异显著(P<0.001);8wk时,Ⅳ与Ⅰ差异显著(P<0.05),Ⅰ、Ⅱ、Ⅲ无显著性差异(P>0.05)。The serum IgM levels of calves of different weeks were different. At the second week, the difference between II and IV was significant (P<0.05), and III and IV were significantly higher than I (P<0.05); at the fourth week, the difference between III and IV was extremely significant (P<0.001), and the difference between II and III was significant. (P<0.05), there was no significant difference between I and II (P>0.05) 0.05), there was a significant difference between III and IV (P<0.001), and the difference between II and III was significant (P<0.05), and the difference between I and II was not significant (P<0.05). P>0.05), there was no significant difference between Ⅲ and Ⅳ (P>0.05); at 6wk, the difference between Ⅱ and Ⅳ groups was extremely significant (P<0.05) (P<0.001), and the difference between Ⅲ and Ⅰ, Ⅱ was significant (P<0.001). <0.05), there was significant difference between IV and I, II (P<0.001); at 8wk, IV and I were significantly different (P<0.05), and I, II, III had no significant difference (P>0.05).

IgM在2wk时,Ⅲ、Ⅳ组较Ⅰ组差异极显著(P<0.001),Ⅲ组较Ⅱ差异显著(P<0.05),Ⅲ组、Ⅳ组差异不显著(P>0.05),Ⅰ、Ⅱ差异不显著(P>0.05);At 2wk, the difference in IgM between groups III and IV was extremely significant (P<0.001), the difference between group III and II was significant (P<0.05), and the difference between groups III and IV was not significant (P>0.05). The difference is not significant (P>0.05);

4wk时,Ⅱ、Ⅲ、Ⅳ组较Ⅰ组差异显著(P<0.05),Ⅱ、Ⅲ、Ⅳ组间差异不显著(P>0.05);At 4wk, there were significant differences between groups II, III, and IV compared with group I (P<0.05), but no significant differences between groups II, III, and IV (P>0.05);

6wk时,Ⅳ较Ⅰ差异显著(P>0.05),Ⅰ、Ⅱ、Ⅲ组间差异不显著(P>0.05);At 6wk, there was a significant difference between IV and I (P>0.05), and there was no significant difference between groups I, II, and III (P>0.05);

8wk时,Ⅳ较Ⅰ、Ⅱ差异显著(P>0.05),Ⅱ组较Ⅰ组差异显著(P<0.05),Ⅲ组较Ⅰ组差异极显著(P<0.001),Ⅲ、Ⅳ组间差异不显著(P>0.05);At 8wk, Ⅳ was significantly different from Ⅰ and Ⅱ (P>0.05), Ⅱ group was significantly different from Ⅰ group (P<0.05), Ⅲ group was significantly different from Ⅰ group (P<0.001), and the difference between Ⅲ and Ⅳ group was not significant. Significant (P>0.05);

表7复合微生态制剂对哺乳犊牛血清免疫球蛋白含量的影响(ng/L)Table 7 Effects of compound probiotics on serum immunoglobulin content of lactating calves (ng/L)

Figure BDA0002593421390000151
Figure BDA0002593421390000151

Figure BDA0002593421390000161
Figure BDA0002593421390000161

4、复合益生菌对哺乳犊牛血清细胞因子含量的影响4. Effects of compound probiotics on serum cytokine levels in lactating calves

如表8所示,不同周龄犊牛血清IL-1β水平不同。第2周时,第2组与第2组比较有显著性差异(P<0.05),而第1、3、4组间差异无显著性(P>0.05);第4周时,Ⅰ、Ⅱ组、Ⅲ、Ⅳ组间差异无显著性(P>0.05),而Ⅲ、Ⅳ组间差异显著(P<0.05);6wk时,Ⅱ、Ⅲ、Ⅳ组间差异有显著性(P<0.05),差异无显著性(P>0.05),但Ⅲ组与Ⅳ组之间有显著性差异(P<0.05);8wk时各组间差异无显著性(P<0.05);As shown in Table 8, the serum IL-1β levels of calves of different ages were different. At the second week, there was a significant difference between the second group and the second group (P<0.05), but there was no significant difference between the first, third, and fourth groups (P>0.05); at the fourth week, I, II There was no significant difference among groups Ⅲ and Ⅳ (P>0.05), while the difference between groups Ⅲ and Ⅳ was significant (P<0.05); at 6wk, there was significant difference among groups Ⅱ, Ⅲ and Ⅳ (P<0.05) , there was no significant difference (P>0.05), but there was a significant difference between group III and group IV (P<0.05); at 8wk, there was no significant difference between groups (P<0.05);

在第2周和第4周,各组间IL-2的差异无显著性(P>0.05);在第6周,第4组与第4组之间的IL-2差异显著(P<0.05);在第3、第3组之间,IL-2的差异无显著性(P>0.05);在第8周,两组之间的差异无显著性(P>0.05)Ⅳ组与Ⅱ、Ⅲ、Ⅳ组比较差异有显著性(P<0.05),而Ⅱ、Ⅲ、Ⅳ组间差异不显著(P>0.05);In the 2nd and 4th week, there was no significant difference in IL-2 among the groups (P>0.05); in the 6th week, there was a significant difference in IL-2 between the 4th and 4th groups (P<0.05). ); there was no significant difference in IL-2 between groups 3 and 3 (P>0.05); at week 8, there was no significant difference between the two groups (P>0.05). There was significant difference between groups Ⅲ and Ⅳ (P<0.05), but there was no significant difference among groups Ⅱ, Ⅲ and Ⅳ (P>0.05).

在第2周和第6周,各组间IL-2水平无显著性差异(P>0.05);在第4周,第Ⅱ、Ⅲ、Ⅳ组之间无显著性差异(P>0.05),而Ⅲ、Ⅳ组间差异显著(P<0.05)。8wk时,Ⅲ组与Ⅳ组比较差异有显著性(P<0.05),而Ⅲ、Ⅳ、Ⅱ、Ⅳ组间差异无显著性(P>0.05),Ⅰ、Ⅱ组间差异无显著性(P>0.05)。At the 2nd and 6th week, there was no significant difference in IL-2 levels among the groups (P>0.05); However, there were significant differences between groups Ⅲ and Ⅳ (P<0.05). At 8wk, there was a significant difference between group III and group IV (P<0.05), but there was no significant difference between groups III, IV, II, and IV (P>0.05), and there was no significant difference between groups I and II (P<0.05). >0.05).

2周时,Ⅱ、Ⅲ、Ⅳ组血清TNF-α无显著性差异(P>0.05),而Ⅱ、Ⅳ组间差异显著(P<0.05);4周时,Ⅰ、Ⅱ、Ⅲ组间无显著性差异(P>0.05),而Ⅱ、Ⅳ组间无显著性差异,Ⅲ、Ⅳ组(P>0.05),Ⅳ组与Ⅰ组比较有显著性差异(P<0.05);6wk时,各组间无显著性差异(P<0.05);8wk时,Ⅰ、Ⅱ、Ⅲ组间差异无显著性(P>0.05),Ⅳ组间差异显著(P<0.05);At 2 weeks, there was no significant difference in serum TNF-α between groups Ⅱ, Ⅲ and Ⅳ (P>0.05), while the difference between groups Ⅱ and Ⅳ was significant (P<0.05); at 4 weeks, there was no significant difference between groups Ⅰ, Ⅱ, Ⅲ. There was a significant difference (P>0.05), but there was no significant difference between groups II and IV. There was a significant difference between groups III and IV (P>0.05), and group IV was significantly different from group I (P<0.05). There was no significant difference between groups (P<0.05); at 8wk, there was no significant difference between groups I, II and III (P>0.05), and there was significant difference between groups IV (P<0.05);

表8复合微生态制剂对哺乳犊牛血清抗氧化指标的影响(ng/L)Table 8 Effects of compound probiotics on serum antioxidant indexes of lactating calves (ng/L)

Figure BDA0002593421390000162
Figure BDA0002593421390000162

Figure BDA0002593421390000171
Figure BDA0002593421390000171

通过表5-6可知,本申请的微生物制剂不仅仅可以达到减少腹泻的次数,还同时刺激犊牛的食欲,增加采食量。在止泻的同时,及时的补充营养,从两方面快速消除犊牛腹泻的不利影响。表7-8也说明了使用本发明的微生物制剂后,犊牛的细胞免疫和体液免疫力快速增强。It can be seen from Tables 5-6 that the microbial preparation of the present application can not only reduce the number of diarrhea, but also stimulate the appetite of calves and increase feed intake. At the same time of stopping diarrhea, timely supplement nutrition can quickly eliminate the adverse effects of calf diarrhea from two aspects. Tables 7-8 also illustrate the rapid enhancement of cellular and humoral immunity of calves after using the microbial preparation of the present invention.

以上所述,仅是本发明实施例的较佳实施例而已,并非对本发明实施例作任何形式上的限制,依据本发明实施例的技术实质对以上实施例所作的任何简单修改、等同变化与修饰,均仍属于本发明实施例技术方案的范围内。The above descriptions are only preferred embodiments of the embodiments of the present invention, and are not intended to limit the embodiments of the present invention in any form. Any simple modifications, equivalent changes and Modifications still fall within the scope of the technical solutions of the embodiments of the present invention.

Claims (7)

1.一种预防犊牛腹泻的复合微生态制剂,其特征在于,所述的复合微生态制剂含有嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌。1. a composite microecological preparation for preventing calf diarrhea, is characterized in that, described composite microecological preparation contains Lactobacillus acidophilus, Saccharomyces boulardii and Bacillus subtilis. 2.根据权利要求1所述的复合微生态制剂,其特征在于,2. composite probiotic preparation according to claim 1, is characterized in that, 所述的嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌的活菌数之比为1-3:1-3:1-3。The ratio of the viable bacterial counts of the Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis is 1-3:1-3:1-3. 3.根据权利要求2所述的复合微生态制剂,其特征在于,3. composite probiotic preparation according to claim 2, is characterized in that, 所述的嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌的活菌数之比为1:2:1或3:3:1。The ratio of the number of viable bacteria of Lactobacillus acidophilus, Saccharomyces bollardii and Bacillus subtilis is 1:2:1 or 3:3:1. 4.根据权利要求3所述的复合微生态制剂,其特征在于,4. composite probiotic preparation according to claim 3, is characterized in that, 所述的嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌的活菌数之比为3:3:1。The ratio of the number of viable bacteria of the Lactobacillus acidophilus, Saccharomyces bodii and Bacillus subtilis is 3:3:1. 5.根据权利要求1所述的复合微生态制剂,其特征在于,5. composite probiotic preparation according to claim 1, is characterized in that, 所述的复合微生态制剂为液态制剂。The composite microecological preparation is a liquid preparation. 6.根据权利要求5所述的复合微生态制剂,其特征在于,6. composite probiotic preparation according to claim 5, is characterized in that, 所述的复合微生态制剂由活菌数浓度均为1×109cfu/mL嗜酸乳杆菌、布拉迪酵母菌和枯草芽孢杆菌配比而成。The composite microecological preparation is formed by the proportion of Lactobacillus acidophilus, Saccharomyces bodii and Bacillus subtilis, all of which have a viable bacteria concentration of 1×10 9 cfu/mL. 7.根据权利要求1所述的复合微生态制剂,其特征在于,7. composite probiotic preparation according to claim 1, is characterized in that, 所述的复合微生态制剂用于预防犊牛大肠杆菌K99导致的腹泻。The compound probiotic preparation is used for preventing diarrhea caused by Escherichia coli K99 in calves.
CN202010702682.6A 2020-07-21 2020-07-21 A compound microecological preparation for preventing calf diarrhea Pending CN111803529A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010702682.6A CN111803529A (en) 2020-07-21 2020-07-21 A compound microecological preparation for preventing calf diarrhea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010702682.6A CN111803529A (en) 2020-07-21 2020-07-21 A compound microecological preparation for preventing calf diarrhea

Publications (1)

Publication Number Publication Date
CN111803529A true CN111803529A (en) 2020-10-23

Family

ID=72865939

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010702682.6A Pending CN111803529A (en) 2020-07-21 2020-07-21 A compound microecological preparation for preventing calf diarrhea

Country Status (1)

Country Link
CN (1) CN111803529A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115044515A (en) * 2022-07-11 2022-09-13 杭州思我特农业科技有限公司 Anti-diarrhea compound probiotic for pets and its application
CN115317399A (en) * 2022-07-07 2022-11-11 湖北真福医药有限公司 Anti-aging composition and preparation method and application thereof
CN114806975B (en) * 2022-06-14 2023-06-23 广东容大生物股份有限公司 A kind of microecological preparation containing gut-derived probiotics and its preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103783315A (en) * 2013-12-18 2014-05-14 北京大北农科技集团股份有限公司 Micro-ecological additive and feed thereof
CN108112987A (en) * 2017-12-12 2018-06-05 广州农信饲料有限公司 A kind of functional preparation for adjusting gastrointestinal health and its preparation method and application
CN109221623A (en) * 2018-12-03 2019-01-18 河南工业大学 A kind of preparation method and application of feed additive
CN111066947A (en) * 2019-12-30 2020-04-28 江苏兴鼎生物工程有限公司 Production method of clostridium butyricum feed additive

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103783315A (en) * 2013-12-18 2014-05-14 北京大北农科技集团股份有限公司 Micro-ecological additive and feed thereof
CN108112987A (en) * 2017-12-12 2018-06-05 广州农信饲料有限公司 A kind of functional preparation for adjusting gastrointestinal health and its preparation method and application
CN109221623A (en) * 2018-12-03 2019-01-18 河南工业大学 A kind of preparation method and application of feed additive
CN111066947A (en) * 2019-12-30 2020-04-28 江苏兴鼎生物工程有限公司 Production method of clostridium butyricum feed additive

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
姚国强: "《乳酸菌微生态制剂防治犊牛腹泻应用研究》", 《中国奶牛》 *
罗满林: "《兽医生物制品学》", 30 April 2019, 中国农业大学出版社 *
高云航: "《实用养牛大全》", 31 May 2003, 延边人民出版社 *
龙广: "《布拉迪酵母菌的研究进展及其在母猪生产中的应用》", 《饲料工业》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114806975B (en) * 2022-06-14 2023-06-23 广东容大生物股份有限公司 A kind of microecological preparation containing gut-derived probiotics and its preparation method and application
CN115317399A (en) * 2022-07-07 2022-11-11 湖北真福医药有限公司 Anti-aging composition and preparation method and application thereof
CN115044515A (en) * 2022-07-11 2022-09-13 杭州思我特农业科技有限公司 Anti-diarrhea compound probiotic for pets and its application
CN115044515B (en) * 2022-07-11 2024-04-16 杭州思我特农业科技有限公司 Composite probiotics for resisting pet diarrhea and application thereof

Similar Documents

Publication Publication Date Title
CN102373172B (en) Enterococcus faecium and application thereof
CN110982760B (en) A strain of Bacillus velesi and its application in the prevention and treatment of swine diarrhea
CN101638627B (en) Bacillus subtilis and application thereof in biological feed additives
CN102226157B (en) Lactobacillus fermentum and application thereof
CN110878267B (en) Lactobacillus salivarius and application thereof
CN113288919B (en) Application of bacillus amyloliquefaciens in preventing diarrhea of weaned piglets
CN111187730B (en) A strain of Bacillus subtilis and its application
CN114806978B (en) Lactobacillus johnsonii SXDT-23 and application thereof
CN114085789B (en) Pediococcus pentosaceus MA.WTPQJ01 and application thereof
CN105543126A (en) Lactobacillus plantarum JM113 and application thereof
CN112574924B (en) Bacillus subtilis strain, microecological preparation and application thereof
CN111803529A (en) A compound microecological preparation for preventing calf diarrhea
CN102391962B (en) Enterococcus faecium preparation agent and manufacturing technology thereof
CN114836358A (en) Lactobacillus reuteri SXDT-32 and application thereof
CN110878266A (en) A strain of Lactobacillus johnsonii and its use
CN106497808A (en) One plant of Lactobacillus salivarius that can be used to produce fermented feed for being isolated from Intestinum Sus domestica road
AU2021105933A4 (en) A Composite Microecological Preparation For Preventing Calf Diarrhea
CN113088468B (en) Lactobacillus casei Ma. GLRGJ1 and application thereof
CN104263683B (en) Bacillus pumilus 315 and its application with prebiotic effect
CN116676214A (en) A kind of Lactobacillus delbrueckii and application thereof
CN115287224B (en) A yak-derived Lactobacillus reuteri strain that improves the intestinal microbial development of the native animal and its application
CN116240124A (en) A strain of Lactobacillus amylovora and its application
CN107058181B (en) A kind of Bacillus subtilis and its separation method and application
CN119020218A (en) Lactobacillus salivarius for ruminants and probiotic preparation and application thereof
CN107043724A (en) A kind of bacillus licheniformis and its separation method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Zhang Wenju

Inventor after: Wu Yanyan

Inventor after: Nie Cunxi

Inventor after: Lu Qicheng

Inventor before: Zhang Wenju

CB03 Change of inventor or designer information
RJ01 Rejection of invention patent application after publication

Application publication date: 20201023

RJ01 Rejection of invention patent application after publication